NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf…
GEN-1013 was studied in an aggressive CT26 murine cancer model using both IT and IV administration.Significant tumor reduction was observed…
MIAMI, April 25, 2025 /PRNewswire/ -- Symphony Robotics, a pioneer in advanced neurosurgical micro-robotics, today announced the appointment of renowned…
Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research event BALTIMORE and PALO…
Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research event BALTIMORE and PALO…
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus…
- Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus…
– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME…
– TK-6302, a supercharged PRAME targeting TCR-T therapy, demonstrates best-in-class preclinical anti-tumor efficacy as compared to current clinical stage PRAME…
Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable…